ProfileGDS5678 / 1452985_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 73% 74% 75% 74% 46% 53% 58% 59% 79% 83% 79% 80% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6757773
GSM967853U87-EV human glioblastoma xenograft - Control 24.6707573
GSM967854U87-EV human glioblastoma xenograft - Control 34.8031174
GSM967855U87-EV human glioblastoma xenograft - Control 45.0521675
GSM967856U87-EV human glioblastoma xenograft - Control 54.8798674
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1643446
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3905953
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5090358
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5096359
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5758479
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0149983
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5407479
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6960480
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6130580